科室小讲课乳腺癌的内分泌治疗 jdg6z4cm.pptVIP

* * Most Breast Cancer Recurrences and Deaths Occur Beyond 5 Years of Tamoxifen The Oxford overview 2000 meta-analysis reviewed outcomes over 15 years of follow-up from diagnosis of early breast cancer, for patients treated with 5 years (years 0-5) of tamoxifen vs control.1,2 The meta-analysis found: About 15% of breast cancer recurrences occur within the first 5 years after starting tamoxifen; over the next 10 years, the incidence is about 18%. About 9% of breast cancer mortality occurs within the first 5 years after starting tamoxifen; for 10 years post-tamoxifen the incidence is 17%. 1. A